Results 141 to 150 of about 49,482 (293)

Rituximab for the treatment of patients with chronic lymphocytic leukemia

Cancer Management and Research, 2010
M Gentile, E Vigna, C Mazzone, E Lucia, AG Recchia, L Morabito2, MG Bisconte, C Gentile, F Morabito1UOC di Ematologia, Azienda Ospedaliera di Cosenza, Italy; 2Servicio de Hematología y Hemoterapia, Hospital Universitario de Canarias, La Laguna,
M Gentile, E Vigna, C Mazzone, et al
doaj  

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody

Clinical and Translational Medicine
Background The blood–brain barrier (BBB) presents a major challenge for the development of monoclonal antibody (mAb)‐based therapies for brain disorders.
Vanessa L. Schumacher, Solen Pichereau, Juliana Bessa, Juergen Bachl, Sylvia Herter, Felix C. Weber, Johannes Auer, Anja Kipar, Michael Winter, Martina Stirn, Michael B. Otteneder, Kevin Brady, Anne Eichinger‐Chapelon, Adrian Roth, Nadine Stokar‐Regenscheit, Nicole Clemann, Shanon Seger, Claudia Senn, Juliane Hönig, Cordula Jany, Elisa Di Lenarda, Alain C. Tissot, Christian Klein, H.‐Christian vonBüdingen, Robert Mader, Mohammed Ullah, Niels Janssen, Eduard Urich   +27 more
doaj   +1 more source

ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells [PDF]

Cancer Immunology Research, 2016
Eugenia, Zah, Meng-Yin, Lin, Anne, Silva-Benedict, Michael C, Jensen, Yvonne Y, Chen   +4 more
openaire   +2 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Preliminary assessment of various additives on the specific reactivity of anti- rHBsAg monoclonal antibodies [PDF]

, 2015
Background: Antibodies have a wide application in diagnosis and treatment. In order to maintain optimal stability of various functional parts of antibodies such as antigen binding sites, several approaches have been suggested.
Mohammadi, S., Shokri, F., Yazdani, Y., Yousefi, M.   +3 more
core  

CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor [PDF]

Journal of Biological Chemistry, 2008
Maria J. Polyak, Haidong Li, Neda Shariat, Julie P. Deans   +3 more
openaire   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

CD20 Antigen Status [PDF]

, 2020
openaire   +1 more source

Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients

Cancer Science, EarlyView.
We described the prognostic impacts of mitochondrial status after neoadjuvant chemotherapy and its association with the tumor microenvironment in esophageal squamous cell carcinoma patients. High Mito‐score after NAC identifies ESCC patients with significantly poorer survival, particularly among those with advanced pathological stages, thereby possibly
Kotaro Sugawara, Shingo Sakashita, Takashi Fukuda, Chiaki Murakami, Daiji Oka, Gulanbar Amori, Yoshifumi Baba, Hiroaki Kanda, Noriko Motoi   +8 more
wiley   +1 more source